Answers are grounded in this paper and cite their sources.
Analysis of excess mortality in Norway reveals significant COVID-19 impacts on specific age groups, suggesting heightened health risks.
The Norwegian Institute of Public Health calculated excess mortality for Norway in 2024 using a reference period that included 2023-a year with significant excess mortality-and concluded there was no excess mortality in 2024. This study estimates excess mortality in 2024 using only pre-pandemic years as the reference, providing a basis for identifying excess COVID-19 related mortality. We estimated excess mortality in 2024 using a negative binomial model trained on 2010-2019 data. Deaths were modelled by age (0, 1-19, 20-39, 40-64, 65-79, 80-89 and 90+ years) and sex, with population offsets. Expected mortality was projected using both a conservative approach where the prediction for 2023 was carried forward to 2024 and a non-conservative linear extrapolation to 2024. The conservative approach estimated 2898 excess deaths (7.0%; 95% prediction interval (PI), 4.9-9.1%) in 2024. Significant excess mortality was observed in age groups 1-19 (45 deaths; 36.6% excess), 20-39 (107 deaths; 17.6% excess), 40-64 (439 deaths; 10.6% excess) and 65-79 (1631 deaths; 13.7% excess). Ages 1-39 and 40-64 accounted for approximately 5% and 15% of total excess mortality, respectively. Persistent excess mortality from 2022 to 2024 suggests a new elevated mortality baseline and a reduction or reversal of Norway's pre-pandemic mortality decline. Although multiple factors may contribute, given sustained excess mortality since 2022, our findings suggest that the unmitigated spread of SARS-CoV-2 in Norway since 2022 can be associated with increased mortality, particularly for those under 65.
No takes yet. Share an insight, caveat, or question.
White et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: